This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Reprints and Permissions Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Edelman, S. V. Articles by Caballero, L. Search for Related Content PubMed PubMed Citation Articles by Edelman, S. V. Articles by Caballero, L. Social Bookmarking                   What's this?

Amylin Replacement Therapy in Patients With Type 1 Diabetes

From the University of California, San Diego.

Correspondence to Steven V. Edelman, MD, University of California, San Diego, Veterans Affairs Medical Center, 3550 La Jolla Village Drive 111G, San Diego, CA 92161 (svedelman{at}vapop.ucsd.edu).

Amylin is a pancreatic ß-cell hormone that is cosecreted with insulin and plays an important physiologic role in glucose homeostasis. Pramlintide is an analogue of amylin recently approved by the Food and Drug Administration and represents the first new treatment for people with type 1 diabetes since the discovery of insulin more than 80 years ago. Pramlintide has been shown to reduce the day-to-day fluctuations in glucose values that are commonly seen despite maximized insulin therapy alone. Additional proven clinical benefits include flattening of the postprandial glucose values, reducing the A1C, and concomitant weight loss. This combination of benefits makes pramlintide an important therapeutic tool for improving the metabolic control and quality of life of people with type 1 diabetes.

CiteULike

Connotea

Del.icio.us

Digg

Reddit

Technorati